Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.41 USD | +0.71% | +6.02% | +5.22% |
Apr. 24 | Precigen, Inc. to Present Late-Breaking Abstract for Pivotal Phase 2 Study Data for PRGN- 2012 AdenoVerse Immunotherapy | CI |
Mar. 25 | North American Morning Briefing : Tech in Focus on -2- | DJ |
Financials (USD)
Sales 2024 * | 5.59M | Sales 2025 * | 45.44M | Capitalization | 351M |
---|---|---|---|---|---|
Net income 2024 * | -89M | Net income 2025 * | -73M | EV / Sales 2024 * | 18.8 x |
Net cash position 2024 * | 246M | Net cash position 2025 * | 157M | EV / Sales 2025 * | 4.27 x |
P/E ratio 2024 * |
-4.19
x | P/E ratio 2025 * |
-6.17
x | Employees | 202 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.7% |
Latest transcript on Precigen, Inc.
1 day | +0.71% | ||
1 week | +6.02% | ||
Current month | -2.76% | ||
1 month | -2.76% | ||
3 months | +2.17% | ||
6 months | +39.60% | ||
Current year | +5.22% |
Managers | Title | Age | Since |
---|---|---|---|
Helen Sabzevari
CEO | Chief Executive Officer | 62 | 19-12-31 |
Harry Thomasian
DFI | Director of Finance/CFO | 62 | 21-09-30 |
Randal Kirk
CHM | Chairman | 70 | 08-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Randal Kirk
CHM | Chairman | 70 | 08-01-31 |
Dean Mitchell
BRD | Director/Board Member | 68 | 09-02-28 |
Jeffrey Perez
PRN | Corporate Officer/Principal | 52 | 14-07-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.02% | 0 M€ | 0.00% | - | |
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 1.41 | +0.71% | 413,594 |
24-04-25 | 1.4 | -1.41% | 611,778 |
24-04-24 | 1.42 | +1.43% | 568,981 |
24-04-23 | 1.4 | +1.45% | 507,021 |
24-04-22 | 1.38 | +3.76% | 890,547 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.22% | 351M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- PGEN Stock